New Research
Methylphenidate, Guanfacine, and Combined Treatment Effects on Electroencephalography Correlates of Spatial Working Memory in Attention-Deficit/Hyperactivity Disorder

https://doi.org/10.1016/j.jaac.2022.06.017Get rights and content
Under a Creative Commons license
open access

Abstract

Objective

The combination of d-methylphenidate and guanfacine (an α-2A adrenergic agonist) may be an effective alternative to either agent as monotherapy in children with attention-deficit/hyperactivity disorder (ADHD). This study investigated the neural mechanisms underlying medication effects using cortical source analysis of electroencephalography (EEG) data.

Method

A total of 172 children with ADHD (aged 7-14; 118 boys) completed an 8-week randomized, double-blind, comparative study with 3 treatment arms: d-methylphenidate, guanfacine, or their combination. EEG modulations of brain oscillations at baseline and end point were measured during a spatial working memory task from cortical sources localized within the anterior cingulate (midfrontal) and primary visual cortex (midoccipital), based on previously reported ADHD and control differences. Linear mixed models examined treatment effects on EEG and performance measures.

Results

Combined treatment decreased midoccipital EEG power across most frequency bands and task phases. Several midoccipital EEG measures also showed significantly greater changes with combined treatment than with monotherapies. D-methylphenidate significantly increased midoccipital theta during retrieval, while guanfacine produced only trend-level reductions in midoccipital alpha during maintenance and retrieval. Task accuracy improved with combined treatment, was unchanged with d-methylphenidate, and worsened with guanfacine. Treatment-related changes in midoccipital power correlated with improvement in ADHD severity.

Conclusion

These findings show that combined treatment ameliorates midoccipital neural activity associated with treatment-related behavioral improvements and previously implicated in visuo-attentional deficits in ADHD. Both monotherapies had limited effects on EEG measures, with guanfacine further showing detrimental effects on performance. The identified midoccipital EEG profile may aid future treatment monitoring for children with ADHD.

Clinical trial registration information

Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder (Project1); https://clinicaltrials.gov/; NCT00429273.

Diversity & Inclusion Statement

We worked to ensure race, ethnic, and/or other types of diversity in the recruitment of human participants. We worked to ensure sex and gender balance in the recruitment of human participants. One or more of the authors of this paper self-identifies as a member of one or more historically underrepresented racial and/or ethnic groups in science. While citing references scientifically relevant for this work, we also actively worked to promote sex and gender balance in our reference list. We actively worked to promote inclusion of historically underrepresented racial and/or ethnic groups in science in our author group. We actively worked to promote sex and gender balance in our author group.

Key words

attention-deficit/hyperactivity disorder
electroencephalography
guanfacine
methylphenidate
treatment effect

Cited by (0)

This work is supported by National Institute of Mental Health (NIMH) grants R01MH116268, “Alpha Oscillations and Working Memory Deficits in ADHD” (S.K.L. and A.L.) and P50MH077248, “Translational Research to Enhance Cognitive Control” (J.T.M.). G.M. was funded by a Klingenstein Third Generation Foundation Fellowship (20212999).

Drs. Michelini and Loo served as the statistical experts for this research.

Author Contributions

Conceptualization: Michelini, Loo

Data curation: Michelini, Lenartowicz, Diaz-Fong, Loo

Formal analysis: Michelini, Lenartowicz, Diaz-Fong, Loo

Funding acquisition: Lenartowicz, Bilder, McGough, McCracken, Loo

Investigation: Michelini, Lenartowicz, Loo

Methodology: Michelini, Lenartowicz, Loo

Project administration: Bilder, McGough, McCracken, Loo

Supervision: Loo

Visualization: Michelini

Writing – original draft: Michelini

Writing – review and editing: Michelini, Lenartowicz, Diaz-Fong, Bilder, McGough, McCracken, Loo

The authors thank all the research staff and students for their assistance on this project and all the participating children and families, without whom this research would not be possible.

Disclosure: Dr. Bilder has received honoraria for consultation or advisory board participation from Acadia Pharmaceuticals, Inc., Atai Life Sciences, and Otsuka Pharmaceutical. Dr. McGough has provided expert testimony for Tris and Takeda Pharmaceuticals and has served on a Data and Safety Monitoring Board for Sunovion. Dr. McCracken has provided expert testimony for Tris Pharmaceuticals and Lannet, has received research contract support from Roche, and has served as a consultant to Roche, GW Biosciences, and Octapharma. Drs. Michelini, Lenartowicz, Loo, and Mr. Diaz-Fong have reported no biomedical financial interests or potential conflicts of interest.